Rocket Pharmaceuticals, Inc. (RCKT) News
Follow Rocket Pharmaceuticals, Inc. (RCKT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Needham upgrades Rocket Pharmaceuticals to Buy after FDA alignment
Needham upgraded Rocket Pharmaceuticals (RCKT) to ‘Buy’ from… after the company aligned with the U.S. FDA on a pivotal study for its experimental genetic disease therapy.
EQUITY | Sep 16, 2026, 12:07 PM UTC
L
RCKT: FDA clears pivotal Danon gene therapy trial; robust pipeline and cash runway support growth
The company is advancing three cardiovascular gene therapy programs, with the Danon disease trial cleared by the FDA to proceed at a recalibrated dose and revised safety regimen. Strong cash reserves support ongoing tria
REGULATION | Sep 15, 2026, 02:55 PM UTC
L
RCKT: FDA cleared resumption of Danon trial; strong pipeline and cash runway support growth
The conference highlighted rapid progress in cardiovascular gene therapy programs, with FDA clearance to resume the Danon disease trial, robust patient identification, and strong long-term safety and efficacy data. Updat
REGULATION | Sep 15, 2026, 02:23 PM UTC
L
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
Rocket Pharmaceuticals Inc. (RCKT) shares rose more than 5% in Tuesday’s opening trade before paring all the gains after the company said it reached alignment with the U.S. Food and Drug Administration on key elements ne
REGULATION | Sep 15, 2026, 02:13 PM UTC
L
Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital
Ratings actions from Benzinga: GMT) Rocket Pharmaceuticals Price Target Maintained With a $11.00/Share by Chardan CapitalRatings actions from Benzinga
NEWS | Sep 15, 2026, 01:49 PM UTC
L
Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial
By Robb M. StewartRocket Pharmaceuticals' shares jumped ahead of the opening bell after the biotechnology company said it was aligned with the Food and Drug Administration on the path forward for its pivotal phase 2 tria
REGULATION | Sep 15, 2026, 12:19 PM UTC
L
Rocket Pharmaceuticals secures FDA alignment on pivotal Phase 2 RP-A501 trial with 12-patient efficacy population
Rocket Pharmaceuticals announced FDA alignment to continue enrollment and dosing in the pivotal Phase 2 RP-A501 trial for Danon disease, confirming a 12—patient pivotal population and 12—month co—primary endpoints.Key Hi
REGULATION | Sep 15, 2026, 11:13 AM UTC
L
RCKT: FDA aligns on pivotal Phase 2 trial design for RP-A501 in Danon disease, supporting accelerated approval
FDA confirmed the pivotal Phase 2 trial design for RP-A501 in Danon disease, including a 12-patient efficacy population and 12-month co-primary endpoints to support potential accelerated approval. Initial safety data sup
REGULATION | Sep 15, 2026, 11:13 AM UTC
L
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, t
REGULATION | Sep 15, 2026, 11:02 AM UTC
L
RCKT - Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
RCKT - Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
Rocket Pharmaceuticals to participate in 2026 Cantor Global Healthcare conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) said it will participate in the 2026 Cantor Global Healthcare conferences.
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
Chardan Capital maintains Rocket Pharmaceuticals Buy, $11 target
Chardan Capital maintained Rocket Pharmaceuticals at Buy, keeping its $11.00/share price target, according to TradingView News via Benzinga ratings actions.
EQUITY | Sep 01, 2026, 12:06 PM UTC
L
Rocket Pharmaceuticals enters severance program; Shah and Wilson agreements
Rocket Pharmaceuticals entered a severance program. Shah and Wilson signed executive agreements.
EQUITY | Aug 27, 2026, 08:14 PM UTC
H
Rocket Pharmaceuticals Reports Positive Safety Update
Rocket Pharmaceuticals announces positive clinical safety update
EQUITY | Aug 03, 2026, 11:01 AM UTC